16408-62-1

Basic information

• Product Name: (IODOMETHYL)CYCLOBUTANE
• Synonyms: (IODOMETHYL)CYCLOBUTANE;Cyclobutane,(iodomethyl)-
• CAS NO: 16408-62-1
• Molecular Formula: C₅H₉I
• Molecular Weight: 196.03
• Mol File: 16408-62-1.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 166.7 °C at 760 mmHg
• Flash Point: 66.9 °C
• Appearance: /
• Density: 1.768g/cm³
• Vapor Pressure: 2.32mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: (IODOMETHYL)CYCLOBUTANE(CAS DataBase Reference)
• NIST Chemistry Reference: (IODOMETHYL)CYCLOBUTANE(16408-62-1)
• EPA Substance Registry System: (IODOMETHYL)CYCLOBUTANE(16408-62-1)

Safety Data

• Hazardous Substances Data: 16408-62-1(Hazardous Substances Data)

Usage

General Description

Iodomethylcyclobutane, also known as 1-iodo-1-methylcyclobutane, is a chemical that falls under the category of organohalogens and more specifically iodoalkanes. It serves a key role in the field of synthetic chemistry, where it's used as a reagent to construct complex chemical structures. The compound has the molecular formula C5H9I and is primarily made up of carbon, iodine, and hydrogen atoms. As a cyclobutane derivative, iodomethylcyclobutane also forms a part of saturated hydrocarbons which include cycloalkanes. Its physical and chemical properties, as well as its safety and handling information, are essential considerations for chemists and scientists who work with this substance regularly.

InChI:InChI=1/C5H9I/c6-4-5-2-1-3-5/h5H,1-4H2

Upstream product

• 4415-82-1 cyclobutanemethanol 
• 7553-56-2 iodine 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 78415-89-1 cyclobutylmethyl chloride 

Downstream Products

• 7766-48-5 1-iodo-4-pentene 
• 1201593-65-8 (S)-2-amino-3-cyclobutylpropanoic acid 
• 478183-60-7 (2S)-2-[[(tert-butoxy)carbonyl]amino]-3-cyclobutylpropanoic acid 
• 1309384-47-1 C₁₈H₂₄O₅ 
• 1309384-39-1 C₁₈H₂₄O₄ 
• 1309384-55-1 (4R,5R)-5-(cyclobutylmethyl)-2-(4-methoxyphenyl)-5-methyl-N-(3-oxo-3-(pentylamino)propyl)-1,3-dioxane-4-carboxamide 
• 1309384-31-3 ((4R,5R)-5-(cyclobutylmethyl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)methanol 
• 300356-78-9 3-cyclobutyl-2-(3,4-dichlorophenyl)propionic acid methyl ester 
• 445305-92-0 Cyclobutylcarbinylsulfonamide 
• 1075233-88-3 N-cyclobutylmethanesulfonamide 
• 1220695-06-6 cyclobutylmethanesulfonyl chloride 
• 1404380-69-3 cyclobutylmethyl phenyl selenide 

Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.

NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.